Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

Fineline Cube Jun 12, 2026
Company Deals

Kelun-Biotech Receives USD 89 Million Settlement Payment from Medilink Therapeutics Over ADC Pipeline Out-Licensing Dispute

Fineline Cube Jun 12, 2026
Company Deals

HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies

Fineline Cube Jun 12, 2026
Company Deals

Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline

Fineline Cube Jun 12, 2026
Company Deals

QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug

Fineline Cube Jun 11, 2026
Policy / Regulatory

China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added

Fineline Cube Jun 12, 2026
Company Drug

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

Fineline Cube Jun 12, 2026
Company Drug

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

Fineline Cube Jun 12, 2026
Company Deals

Shanghai Xinhengrui Medical Technology Secures Series A Funding for Heart Failure Device Development

Fineline Cube Jul 17, 2023

Shanghai Xinhengrui Medical Technology Co., Ltd, a manufacturer of heart failure devices, has successfully raised...

Company Deals

Beyond Therapeutics Secures Tens of Millions in Pre-Series A Financing for Ophthalmology and Oncology Pipeline

Fineline Cube Jul 17, 2023

Beyond Therapeutics Co., Ltd., a biotechnology company based in Suzhou with a focus on ophthalmology...

Company Drug

Mabwell Bioscience Receives NMPA Approval to Launch 9MW2921 Clinical Study

Fineline Cube Jul 17, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it...

Company Deals Hospital

Centre Medical Secures Tens of Millions in Series A Financing to Expand Globally

Fineline Cube Jul 17, 2023

Centre Medical, a Hong Kong-based cardiovascular specialized medical services provider, has reportedly raised tens of...

Company Drug

TransThera Sciences’ TT-00420 Receives Breakthrough Designation for Cholangiocarcinoma Treatment

Fineline Cube Jul 17, 2023

The Center for Drug Evaluation (CDE) website has indicated that Nanjing-based TransThera Sciences (Nanjing), Inc.’s...

Company Drug

Shenzhen Salubris Pharmaceuticals’ SAL0120 for IgA Nephropathy Accepted for NMPA Review

Fineline Cube Jul 17, 2023

Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that the National Medical Products Administration...

Policy / Regulatory

NHSA Unveils 2023 Flying Inspection Plan for Medical Insurance Fund Oversigh

Fineline Cube Jul 17, 2023

The National Healthcare Security Administration (NHSA) has released its 2023 Basic Medical Insurance (BMI) Fund...

Company Drug

Betta Pharmaceuticals’ MCLA-129 Combo Therapy for NSCLC Gets NMPA Clinical Approval

Fineline Cube Jul 17, 2023

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that it has received clinical trial...

Company Drug

Pfizer Launches Phase III Trial for Quadrivalent Influenza modRNA Vaccine in Argentina

Fineline Cube Jul 17, 2023

Global pharmaceutical giant Pfizer (NYSE: PFE) has commenced recruitment in Argentina for a Phase III...

Company Drug

Zai Lab Initiates Phase III Trial for Bemarituzumab in First-Line Gastric Cancer Treatment

Fineline Cube Jul 17, 2023

China-based biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the first patient...

Company Drug Policy / Regulatory

Chile Expands Financial Coverage for AbbVie’s RSV Prophylaxis Synagis

Fineline Cube Jul 17, 2023

Chile’s Ministry of Health (MINSAL) has announced an immediate expansion in the coverage under its...

Company Deals

Silence Therapeutics Receives $4 Million Milestone Payment from Hansoh Pharmaceutical

Fineline Cube Jul 14, 2023

UK-based Silence Therapeutics plc (NASDAQ: SLN) has announced the receipt of a $4 million milestone...

Company

Harbour BioMed Reports First-Ever Profit in H1 2023 Interim Financial Results

Fineline Cube Jul 14, 2023

Harbour BioMed (HKG: 2142), a biotech company with operations in Suzhou, China, Cambridge in the...

Company Deals

InnoCare Pharma and ArriVent Biopharma Partner on SHP2 Inhibitor and EGFR Inhibitor Combination

Fineline Cube Jul 14, 2023

China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced a clinical development collaboration with US-based...

Company Drug

GSK’s Cabotegravir Receives NMPA Approval for HIV Treatment in China

Fineline Cube Jul 14, 2023

The National Medical Products Administration (NMPA) has granted marketing approval for GlaxoSmithKline’s (GSK, NYSE: GSK)...

Company Medical Device

Beijing Tinavi Medical’s Knee Replacement Navigation System Approved by NMPA

Fineline Cube Jul 14, 2023

Beijing Tinavi Medical Technologies Co., Ltd (SHA: 688277) has received marketing approval from the National...

Company Deals

GeneQuantum Healthcare and Aimed Bio Expand Partnership to Develop Five Novel ADC Drugs

Fineline Cube Jul 14, 2023

China-based GeneQuantum Healthcare has unveiled a new agreement to expand its existing partnership with South...

Company Drug

BeiGene’s Brukinsa Receives US FDA Review for Relapsed/Refractory Follicular Lymphoma sNDA

Fineline Cube Jul 13, 2023

China-based biotechnology company BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration...

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Gains New Indication Approval in China for HER2-Low Breast Cancer

Fineline Cube Jul 13, 2023

Partners AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have announced that their co-developed...

Company Policy / Regulatory

US FDA Approves Additional Shipments of Qilu Pharmaceutical’s Cisplatin to Address Shortage

Fineline Cube Jul 13, 2023

The US Food and Drug Administration (FDA) is maintaining its reliance on China-based Qilu Pharmaceutical...

Posts pagination

1 … 519 520 521 … 682

Recent updates

  • Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal
  • Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC
  • Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria
  • China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added
  • Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

Company Drug

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

Company Drug

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

Policy / Regulatory

China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.